Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented Pharma Company with presence in 55 countries. Indoco is a USD 198mn company with over 6000 Indocoites including over 300 skilled scientists. The company has 9 mfg. facilities, 6 for finished dosages and 3 for APIs, supported by a state-of-the-art R&D centre at Rabale, Navi Mumbai,backed by CRO at Hyd. The facilities have been approved by various regulatory authorities like USFDA, UK-MHRA, MOH Botswana, TGA-Australia, NMRA - Sri Lanka, FMHACA-Ethiopia, SUKL – Czech Republic, ANVISA-Brazil, SAHPRA- SA, NDA-Uganda, MOH – Oman, INVIMA - Colombia, Health Canada, TFDA-Tanzania, MCA- Zimbabwe, MOHP UAE, etc. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments like Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM,Oxipod,Cital, Sensoform, Sensodent-KF, Cloben-G, Glychek, Kidodent,Carmicide, Rexidin,MCBM69, Methycal,Homide & Cal-Aid. On the international front, Indoco has tie-ups with large generic companies across the globe. Indoco has carved a place for itself in the international arena and is exporting a number of generic products in the Regulated and Emerging Markets. Indoco’s branded formulations are promoted in Emerging Markets of South East Asia, Africa, Latin America and CIS countries. The Company participates in various tenders floated by authorities from different countries. Indoco has tie-ups with large generic companies across the globe and works in close coordination with its customers for leveraging core competencies. Indoco Analytical Solutions division has been carved to serve customers for their analytical research needs. AnaCipher CRO, Hyderabad, is a USFDA inspected facility providing clinical trial solutions, BA/BE/Phase I/Phase studies.